Celecoxib Lipid Prodrugs for Metabolic Disease
Summary
US Patent 12611415B2 (B2 kind, 10 claims) issued to MONASH UNIVERSITY on 2026-04-28. The patent covers methods of treating metabolic diseases including obesity, insulin resistance, and type 2 diabetes with celecoxib lipid prodrugs that promote transport of the pharmaceutical agent to the lymphatic system and enhance release of the parent agent.
“The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
US Patent 12611415B2 was granted to MONASH UNIVERSITY on April 28, 2026, covering methods and compounds for treating metabolic diseases including obesity, insulin resistance, and type 2 diabetes using celecoxib lipid prodrugs. The prodrugs are designed to promote lymphatic transport of the pharmaceutical agent and enhance release of the parent drug. The patent has 10 claims and CPC classifications including A61K 31/635, A61K 31/404, and A61P 3/04.
Pharmaceutical companies and drug manufacturers developing COX-2 inhibitor formulations or treatments for metabolic disease may wish to review freedom-to-operate positions relative to this patent. The patent's emphasis on lymphatic targeting and lipid prodrug delivery represents a specific formulation strategy that competitors in the metabolic disease therapeutic space should consider when designing drug delivery approaches.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compounds for treatment of metabolic disease
Grant US12611415B2 Kind: B2 Apr 28, 2026
Assignee
MONASH UNIVERSITY
Inventors
Natalie Trevaskis, Christopher John Porter, Tim Quach, Sifei Han, Enyuan Cao, Luojuan Hu, Matthew Watt
Abstract
The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.
CPC Classifications
A61K 31/635 A61K 31/404 A61P 3/04
Filing Date
2020-09-21
Application No.
17753936
Claims
10
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.